Thrombotic microangiopathy-like disorder after living-donor liver transplantation: A single-center experience in Japan

Table 2 Previous series and case reports with TMA after liver transplantation

Year	The firstauthor	Patientnumber	PEtherapy	Focus	Diagnostic advices	Therapeutic advices
2008	Oya	1	+	The risk factor TMA, the relation of TMA and ABO compatibility	-	Reduction of CNI PE Intravenous infusion of high-dose γ-globulin
2007	Miyata	4	+	Plasminogen activator inhibitor type 1, the relation of TMA and ABO compatibility, early diagnosis of TMA for appropriate therapy	Plasminogen activator inhibitor type 1 the vWF value	Early recognition of TMA
2007	Akamatsu	1	+	The reation of TMA and CNI	-	CNI conversion
2006	Nishi	18	+	Poor outcome of TMA recipients PE therapy for TMA, the risk factors of TMA after LDLT	-	PE was not sufficient
2005	Banno	5	+	The analyzer of red blood cell fragmentation	Red blood cell fragmentation	-
2005	Taura	10	+	The relation of TMA and HCV infection		PE CNI conversion
2003	Nakazawa	1	+	The vWF-cleaving protease, the inhibitors against this protease	The vWF-cleaving protease, the inhibitors against this protease	PE
2003	Ramasubbu	1	+	The relation of TMA and CMV	-	-

PE: Plasma exchange; TMA:Thrombotic microangiopathy; CNI: Calcineurin inhibitor; LDLT: Living-donor liver transplantation; HCV: Hepatitis C virus; vWF: von Willebrand factor; CMV: Cytomegalovirus.